Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable

I'm one of what feels like a handful of people willing to put positive opinions on cell therapy companies, and I'm on record as having bullish sentiment on Autolus Therapeutics (NASDAQ: AUTL ). When last II have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investin ...